Posts for Ticker ‘MDVN’

Full 2009 ASCO Cancer & Oncology Primer (ABII, AEZS, ALTH, AMGN, APPA, ARQL, BMY, CLDX, CELG, CTIC, CGRB, LLY, EXEL, GHDX, GSK, IMGN, MEDX, MDVN, MITI, OGXI, OSIP, PPHM, PFE, ROSG, SNTA, TRBN, ZIOP, ZGEN)

We have compiled an updated lengthy 2009 American Society of Clinical Oncology, or ASCO, document showing many company cancer data presentations slated to start this weekend.   This is broken down in drug and biotech companies with share values, ranges, and recent developments for the following drug and biotech companies:  Abraxis BioScience, Inc. (NASDAQ:ABII), AEterna Zentaris Inc. (NASDAQ: AEZS), Allos Therapeutics, Inc. (NASDAQ: ALTH), Amgen Inc. (NASDAQ: AMGN), A.P. Pharma, Inc. (Nasdaq: APPA), Arqule Inc. (NASDAQ: ARQL), Bristol-Myers Squibb (NYSE: BMY), Celldex Therapeutics (NASDAQ: CLDX), Celgene Corporation (NASDAQ: CELG), Cell Therapeutics (NASDAQ: CTIC), Cougar Biotechnology, Inc. (NASDAQ: CGRB), Eli Lilly and Company (NYSE: LLY), Exelixis (NASDAQ: EXEL), Genomic Health, Inc. (NASDAQ: GHDX), GlaxoSmithKline (NYSE: GSK) , Immunogen (NASDAQ: IMGN), Medarex (NASDAQ: MEDX), Medivation, Inc. (NASDAQ: MDVN), Micromet, Inc. (NASDAQ: MITI), OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), OSI Pharmaceuticals (NASDAQ: OSIP), Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), Pfizer Inc. (NYSE: PFE), Rosetta Genomics (NASDAQ:ROSG), Synta Pharmaceuticals (NASDAQ: SNTA), Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN), ZIOPHARM Oncology (NASDAQ: ZIOP), and ZymoGenetics, Inc. (NASDAQ: ZGEN).

The full presentation can be seen at BioHealthInvestor.com.

JON C. OGG
May 27, 2009

Posted on: May 27, 2009 – 1:34 pm in Biotech, Drug companies, FDA, Medical, Pharmaceuticals, , , , , , , , , , , , , , , , , , , , , , , , , , , ,

Previewing 2009 ASCO Abstracts (ABII, ALTH, ARQL, CLDX, CTIC, CGRB, LLY, EXEL, GHDX, GSK, IMGN, MEDX, MDVN, OGXI, OSIP, PPHM, PFE, SNTA, ZIOP)

We are just about to get the first round of abstracts from companies presenting data at this year’s American Society of Clinical Oncology meeting for 2009.  At BioHealthInvestor.com we compiled a brief summary for companies such as Abraxis BioScience, Inc. (NASDAQ:ABII), Allos Therapeutics, Inc. (NASDAQ: ALTH), Arqule Inc. (NASDAQ: ARQL), Celldex Therapeutics (NASDAQ: CLDX), Cell Therapeutics (NASDAQ: CTIC), Cougar Biotechnology, Inc. (NASDAQ: CGRB), Eli Lilly and Company (NYSE:  LLY), Exelixis (NASDAQ: EXEL), Genomic Health, Inc. (NASDAQ: GHDX), GlaxoSmithKline (NYSE: GSK) , Immunogen (NASDAQ: IMGN), Medarex (NASDAQ: MEDX), Medivation, Inc. (NASDAQ: MDVN), OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), OSI Pharmaceuticals (NASDAQ: OSIP), Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), Pfizer Inc. (NYSE: PFE), Synta Pharmaceuticals (NASDAQ: SNTA), and ZIOPHARM Oncology (NASDAQ: ZIOP).

You can see that full pre-report here at BiohealthInvestor.com.  As always be advised that there may be new sets of data released between now and the actual meeting from May 29 to June 2, 2009 in Orlando, Florida.

Posted on: May 14, 2009 – 4:56 pm in Biotech, Drug companies, Medical, Pharmaceuticals, , , , , , , , , , , , , , , , , , ,

The Day In Biotech Stocks (January 28, 2008) (ACOR, BIIB, CELG, PHRM, CRXX, LIPD, MDVN, PCOP)

Acorda Therapeutics inc. (NASDAQ: ACOR) showed late stage trial results on its drug candidate Fampridine-SR for treating multiple sclerosis.  This data showed that Fampridine, which is designed to treat multiple sclerosis, did not increase patients’ QT interval Associated with Arrhythmia more than a placebo did.  Shares were up $4.29 at $26.07 mid-day.

Amylin Pharmaceuticals Inc. (NASDAQ: AMLN) is set to report earnings after the closing bell, with First Call estimates at -$0.44 EPS on revenues of $202.58 million Shares were up less than 1% at $32.74 on the day ahead of earnings.

Carl Icahn has nominated three individuals for the board of directors in Biogen-Idec (NASDAQ: BIIB) in his activist efforts to move the shares.  Biogen-Idec shares were down $0.90 to $58.02 mid-day.

Celgene Corporation (NASDAQ: CELG) was cleared today by German regulation to proceed with its acquisition of Pharmion. Stocks are up over 3% to $53.31 at mid-day. Pharmion Corp. (NASDAQ: PHRM) shares were up 1.8% to $67.44.

CombinatoRx Inc. (NASDAQ: CRXX) shares fell almost 7% to $4.80 mid-day on thin trading volume.  Technically there was no news today, although this followed guidance last week of losses below view.

Lipid Sciences, Inc. (NASDAQ: LIPD) announced positive trial results in non-human SIV-infected primates in its proprietary deplidated autogolous virus vaccine. Share prices were up more than 15% or $0.09 to $0.65 at mid-day.

Medivation, Inc. (NASDAQ: MDVN) rose after it announced that, based on its end-of-Phase 2 meeting with the FDA, it plans to begin a pivotal confirmatory Phase III trial of Dimebon for mild-to-moderate Alzheimer’s Disease in the second quarter of 2008.  Shares rose $2.36 to $17.21 by mid-day on this data.

Pharmacopeia, Inc. (NASDAQ: PCOP) shares fell over 10% to $4.37 at mid-day on thin-trading volume. There has been no recent news.

Jon C. Ogg
January 28, 2008

Posted on: January 28, 2008 – 1:43 pm in Biotech, , , , , , , , , , ,

Alzheimer’s Data Pumps Medivation & Neurochem (MDVN, NRMX)

Some new data is helping two small biotech stocks today at the Alzheimer’s Association International Conference on Prevention of Dementia in Washington, DC.  The latest figure showed 26.6 million people worldwide are living with Alzheimer’s and that figure is expected to quadruple by the year 2050.  In March, the Alzheimer’s Association reported that there are now more than 5 million people in the United States living with Alzheimer’s.

Medivation (MDVN) shares are trading up 30% at what will be a 52-week high after it its Alzheimer’s treatment Dimebon significantly improved symptoms of the disease over one year.  After a one-year mark, patients with mild to moderate Alzheimer’s taking its Dimebon showed benefits in cognition, overall clinical function, normal daily living activities, and improved behavioral problems compared with those patients receiving the placebo.

Neurochem (NRMX) is up over 4% pre-market after release of data on its Alzhemed, although the company readily admits that there is a long ways to go and that the data analysis will still be months away.

In the past we covered some of the Alzheimer’s stocks after a Barron’s piece on the subject, although some of the data from the companies with ‘promising treatments’ has changed.

Here is a full list of the news releases from the conference.

Jon C. Ogg
June 11, 2007

Jon Ogg can be reached at jonogg@247wallst.com; he does not own securities in the companies he covers.

Posted on: June 11, 2007 – 8:29 am in Biotech, ,

Pre-Market Stock News (June 11, 2007)

(ADLR) Adolor said a complete response to the POI ‘Approvable’ Letter now targeted for 3Q 2007.
(ALXN) Alexion Pharm says studies show efficacy and safety of it’s Soliris in broad population of PNH patients in Phase III studies examining Soliris for the treatment of paroxysmal nocturnal hemoglobinuria.
(BYBI) Backyard Burgers agrees to be acquired for $6.50 cash per share.
(CHINA) CDC Corp making a gaming company acquisition.
(CSGS) CSG Systems is paying $23.5M cash to acquire private ComTec.
(CUP) Peru Copper gets a friendly takeover offer from Aluminum of China.
(EME) EMCOR raised guidance and announced a 2-1 stock split.
(ENDO) Endo pharmaceuticals’ FROVA Phase III study data showed short-term prevention treatment reduces frequency and severity of menstrual migraine.
(ERIC) Ericsson in GSM expansion pact with China Mobile.
(GERN) Geron says research indicates its embryonic stem cell based therapy for spinal cord injury evades direct attack response by the human immune system.
(GOOG) Google announced search and ad pact with Sina in China.
(GOL) Gol Intelligent Airlines said Continental will sell its tickets for travel to Brazil and South America.
(IBM) IBM paying close to $750 million to acquire Telogic AB in Sweden.
(IMCL) Imclone said FDA accepted and granted priority review of ERBITUX sBLA for overall survival in patients with advanced colorectal cancer.
(JOSB) Jos. A. Bank $0.45 EPS vs $0.42e.
(MDVN) Medivation’s Dimebon maintains statistically significant benefit on all five efficacy endpoints in Alzheimer’s disease after one year of therapy
(NGA) North American Galvanizing trades ex-split to reflect a 3-2 stock split.
(NRMX) Neurochem presents update on Alzhemed, but said that no predictions or conclusions can yet be made regarding the outcome of the Phase III study.
(OI) Owen-Illinois is selling its plastics unit to rexam for $1.8 Billion.
(OSUR) OraSure received a CE mark of approval from the EU for its OraQuick rapid HIV test.
(PRGS) Progress Software added one of the Dow Jones news feeds to its algorithmic trading platform.
(PRW) Pro-Pharmaceutical submits data to begin a 505B2 filing with FDA for new formulation of Irinotecan for potential cancer treatment indications.
(RIMG) Rimage announced a $6.5M order from new major national retail customer.
(SINA) Sina in strategic search and ad partnership with Google in China.
(TRLG) True Religion CEO reduced holdings of 2.3 million shares in a private placement.

Jon C. Ogg
June 11, 2007

Jon Ogg can be reached at jonogg@247wallst.com; he does not own securities in the companies he covers.

Posted on: June 11, 2007 – 6:48 am in Pre-Market Activity, , , , , , , , , , , , , , , , , , , ,